Key finding — Psilocybin-assisted therapy produced large, rapid, and sustained antidepressant effects, with most participants meeting response criteria and about half in remission at the four-week follow-up.
Study at a glance
| Field | Detail |
|---|---|
| Institution | Johns Hopkins University |
| Design | Randomized, waitlist-controlled clinical trial |
| Sample size | 24 participants |
| Intervention | Two psilocybin doses with supportive psychotherapy, immediate vs. delayed treatment |
| Year | 2021 |
| Condition | Major depressive disorder |
| Journal | JAMA Psychiatry |
| Evidence | emerging |
Limitations
Small sample, waitlist control (not active placebo), and a screened population; effects may be inflated by expectancy.
Editorial note
A frequently cited randomized trial extending psilocybin's antidepressant signal from treatment-resistant to broader major depressive disorder, again under structured therapeutic support.
Summary written by MMI Editorial for clarity. Always consult the primary source for full methodology and results. The confidence rating reflects our assessment of evidence strength.